Analystreport

Protagonist Therapeutics Inc (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at BMO Capital Markets. They now have a $13.00 price target on the stock.

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com